Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-11-03

Clinical Trial Update: Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ITI-007 (lumateperone) as monotherapy for bipolar depression has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Caplyta (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Bipolar Depression | Phase 3 | Status: COMPLETED | Results posted: 2025-11-03